Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991317347> ?p ?o ?g. }
- W2991317347 abstract "Abstract Background The phase II trial evaluated the efficacy and safety of low starting dose of afatinib in patients with advanced epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). In primary analysis, progression free survival (PFS) met the primary endpoint. Here, we report updated survival outcomes. Methods This study was a multi-center, single-arm, open-label phase II trial. Treatment-naive patients with common EGFR mutation-positive NSCLC were treated with afatinib starting at a dose of 20 mg/day. If tolerated, the dose is increased by 10- mg increments up to 50mg/day. PFS and overall survival (OS) were re-evaluated at the final data cut-off point (October 2018). Results 46 patients were enrolled. Median age was 73 years (range, 43-86). The median follow-up was 31.9 months. Median PFS of entire population was 15.2 months (95% confident interval (CI), 13.2–21.2), and 2-year PFS rate was 27.7% (95% CI, 17.1-44.7). Median OS was not estimated, and the 2-year overall survival was 76.1% (95% CI, 64.7-89.5). Performance status (PS) and existence of brain metastases at study entry were revealed to have significant impact on the survival with Cox-regression test. Among patients with disease progression on afatinib (n = 36), rebiopsy was performed on 29 patients, and T790M was proved positive on 14 patients. Twelve out of the 14 patients positive for T790M received osimertinib as a second line therapy. Median time from enrollment to progression on the osimertinib (PFS2) was 32.6 months (95%CI: 20.5-NE). Conclusions Low starting dose afatinib therapy demonstrated promising OS outcome. PS and existence of brain metastases were predictive factors of this therapy. Clinical trial identification UMIN 000016444. Legal entity responsible for the study Kyoto Thoracic Oncology Research Group. Funding Has not received any funding. Disclosure T. Yokoyama: Honoraria (self): Boehringer Ingelheim Japan; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Ono pharmaceutical; Honoraria (self): MSD. H. Yoshioka: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Eli Lilly Japan; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Novartis; Honoraria (self): Merck Serono; Honoraria (self): Kyowa Kirin; Honoraria (self): AstraZeneca; Honoraria (self): Ono pharmaceutical; Honoraria (self): Daiichi Sankyo; Honoraria (self): MSD. D. Fujimoto: Honoraria (self), Research grant / Funding (self): AstraZeneca KK; Honoraria (self): Ono Pharmaceutical Co Lt; Honoraria (self): Bristol-Myers Squibb Co Ltd; Honoraria (self): Taiho Pharmaceutical Co ; Honoraria (self), Research grant / Funding (self): Chugai Pharmaceutical Co Ltd; Honoraria (self): MSD KK; Honoraria (self): Boehringer Ingelheim Japan Inc; Honoraria (self): Eli Lilly Japan KK. K. Hirano: Honoraria (self): Boehringer Ingelheim Japan. T. Ishida: Honoraria (self): Boehringer Ingelheim Japan. T. Hirai: Research grant / Funding (institution): Boehringer Ingelheim Japan. All other authors have declared no conflicts of interest." @default.
- W2991317347 created "2019-12-05" @default.
- W2991317347 creator A5005128882 @default.
- W2991317347 creator A5025251965 @default.
- W2991317347 creator A5034733511 @default.
- W2991317347 creator A5036577393 @default.
- W2991317347 creator A5044214575 @default.
- W2991317347 creator A5048538074 @default.
- W2991317347 creator A5049263315 @default.
- W2991317347 creator A5050420337 @default.
- W2991317347 creator A5055024048 @default.
- W2991317347 creator A5063376504 @default.
- W2991317347 creator A5063487121 @default.
- W2991317347 creator A5066147617 @default.
- W2991317347 creator A5066413780 @default.
- W2991317347 creator A5081905843 @default.
- W2991317347 creator A5086802812 @default.
- W2991317347 creator A5091096026 @default.
- W2991317347 date "2019-11-01" @default.
- W2991317347 modified "2023-09-26" @default.
- W2991317347 title "Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)" @default.
- W2991317347 doi "https://doi.org/10.1093/annonc/mdz437.007" @default.
- W2991317347 hasPublicationYear "2019" @default.
- W2991317347 type Work @default.
- W2991317347 sameAs 2991317347 @default.
- W2991317347 citedByCount "0" @default.
- W2991317347 crossrefType "journal-article" @default.
- W2991317347 hasAuthorship W2991317347A5005128882 @default.
- W2991317347 hasAuthorship W2991317347A5025251965 @default.
- W2991317347 hasAuthorship W2991317347A5034733511 @default.
- W2991317347 hasAuthorship W2991317347A5036577393 @default.
- W2991317347 hasAuthorship W2991317347A5044214575 @default.
- W2991317347 hasAuthorship W2991317347A5048538074 @default.
- W2991317347 hasAuthorship W2991317347A5049263315 @default.
- W2991317347 hasAuthorship W2991317347A5050420337 @default.
- W2991317347 hasAuthorship W2991317347A5055024048 @default.
- W2991317347 hasAuthorship W2991317347A5063376504 @default.
- W2991317347 hasAuthorship W2991317347A5063487121 @default.
- W2991317347 hasAuthorship W2991317347A5066147617 @default.
- W2991317347 hasAuthorship W2991317347A5066413780 @default.
- W2991317347 hasAuthorship W2991317347A5081905843 @default.
- W2991317347 hasAuthorship W2991317347A5086802812 @default.
- W2991317347 hasAuthorship W2991317347A5091096026 @default.
- W2991317347 hasBestOaLocation W29913173471 @default.
- W2991317347 hasConcept C121608353 @default.
- W2991317347 hasConcept C126322002 @default.
- W2991317347 hasConcept C141071460 @default.
- W2991317347 hasConcept C143998085 @default.
- W2991317347 hasConcept C203092338 @default.
- W2991317347 hasConcept C2776256026 @default.
- W2991317347 hasConcept C2776694085 @default.
- W2991317347 hasConcept C2777626846 @default.
- W2991317347 hasConcept C2777930144 @default.
- W2991317347 hasConcept C2778087573 @default.
- W2991317347 hasConcept C2779438470 @default.
- W2991317347 hasConcept C2780580887 @default.
- W2991317347 hasConcept C2780586478 @default.
- W2991317347 hasConcept C2780739268 @default.
- W2991317347 hasConcept C2908647359 @default.
- W2991317347 hasConcept C31760486 @default.
- W2991317347 hasConcept C535046627 @default.
- W2991317347 hasConcept C71924100 @default.
- W2991317347 hasConcept C99454951 @default.
- W2991317347 hasConceptScore W2991317347C121608353 @default.
- W2991317347 hasConceptScore W2991317347C126322002 @default.
- W2991317347 hasConceptScore W2991317347C141071460 @default.
- W2991317347 hasConceptScore W2991317347C143998085 @default.
- W2991317347 hasConceptScore W2991317347C203092338 @default.
- W2991317347 hasConceptScore W2991317347C2776256026 @default.
- W2991317347 hasConceptScore W2991317347C2776694085 @default.
- W2991317347 hasConceptScore W2991317347C2777626846 @default.
- W2991317347 hasConceptScore W2991317347C2777930144 @default.
- W2991317347 hasConceptScore W2991317347C2778087573 @default.
- W2991317347 hasConceptScore W2991317347C2779438470 @default.
- W2991317347 hasConceptScore W2991317347C2780580887 @default.
- W2991317347 hasConceptScore W2991317347C2780586478 @default.
- W2991317347 hasConceptScore W2991317347C2780739268 @default.
- W2991317347 hasConceptScore W2991317347C2908647359 @default.
- W2991317347 hasConceptScore W2991317347C31760486 @default.
- W2991317347 hasConceptScore W2991317347C535046627 @default.
- W2991317347 hasConceptScore W2991317347C71924100 @default.
- W2991317347 hasConceptScore W2991317347C99454951 @default.
- W2991317347 hasLocation W29913173471 @default.
- W2991317347 hasOpenAccess W2991317347 @default.
- W2991317347 hasPrimaryLocation W29913173471 @default.
- W2991317347 hasRelatedWork W2978188155 @default.
- W2991317347 hasRelatedWork W2978242011 @default.
- W2991317347 hasRelatedWork W2978268429 @default.
- W2991317347 hasRelatedWork W2978412047 @default.
- W2991317347 hasRelatedWork W2978468976 @default.
- W2991317347 hasRelatedWork W2978547119 @default.
- W2991317347 hasRelatedWork W2978637105 @default.
- W2991317347 hasRelatedWork W2978648769 @default.
- W2991317347 hasRelatedWork W2978855448 @default.
- W2991317347 hasRelatedWork W2978984983 @default.
- W2991317347 hasRelatedWork W2979152494 @default.
- W2991317347 hasRelatedWork W2979175954 @default.
- W2991317347 hasRelatedWork W2979192637 @default.
- W2991317347 hasRelatedWork W2988313406 @default.
- W2991317347 hasRelatedWork W2989822426 @default.